Apellis Pharmaceuticals APLS
Citron shorts Apellis, arguing its new Geographic Atrophy drug Syfovre faces an imminent FDA warning as AAO ophthalmologists reject it 83%-17% and vasculitis cases mount.
Thesis
Apellis Pharmaceuticals' Syfovre — the first FDA-approved Geographic Atrophy treatment, launched in 2023 without an FDA advisory committee and marketed by Henry 'The Fonz' Winkler — faces mounting clinical and safety problems that Citron argues will trigger a warning label or pause. At the November 2023 American Academy of Ophthalmology meeting, panelists voted 83% against Syfovre being an 'acceptable' therapy, with top vitreoretinal surgeon Dr. Richard Spaide citing QALYs approaching zero and the Wolfe Eye Clinic reporting complications in 1 of 28 injections. A Freedom of Information Act request reveals at least 12 vasculitis cases in the past month, contradicting CEO Cedric Francois's claim of a lone September case and raising potential securities-fraud exposure. Citron draws an explicit analogy to Novartis's Beovu, whose physician usage collapsed after similar ASRS vasculitis warnings, implying substantial downside for APLS.
SCQA
Apellis launched Syfovre in early 2023 as the first FDA-approved treatment for Geographic Atrophy, bypassing an FDA advisory committee and generating Wall Street excitement aided by a Henry Winkler celebrity marketing campaign.
Real-world vasculitis complications are accumulating: Wolfe Eye Clinic saw 1 in 28 injections cause harm, the AAO 2023 audience voted 83% against acceptability, and FOIA filings contradict the CEO's claim of a single case.
Citron calls for the FDA to impose a warning label or pause Syfovre, and flags CEO Cedric Francois's understatement of vasculitis cases on the Q3 earnings call as potential securities fraud warranting regulator review.
Citron implies APLS will follow Novartis's Beovu, whose physician usage collapsed permanently after ASRS vasculitis warnings — a trajectory that would inflict heavy damage on Apellis's financials and share price.
The three reasons
- 1
AAO 2023 ophthalmologists voted 83%-17% that Syfovre is not an acceptable therapy
- 2
Wolfe Eye Clinic observed complications in 1 of 28 Syfovre injections, urging a warning or pause
- 3
FOIA reveals 12+ vasculitis reports vs CEO's claim of a single September case — potential securities fraud
Primary demands
- FDA issue a warning label on Syfovre or pause the drug
- Regulators investigate CEO Cedric Francois's disclosures for possible securities fraud
- Shareholders reassess Apellis given likelihood of Beovu-style physician abandonment
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Novartis Beovu (ASRS vasculitis warnings triggered physician abandonment, Feb 2020)
- Henry Winkler / One Reverse Mortgages shutdown ('Fonzi Scheme')
Notable slides (6)
Notes
Short-seller research note structured as a Word-style memo with embedded screenshots from AAO 2023 presentations (Spaide, Wolfe/Johnson), a borrowed Jefferies Beovu volume chart, and FDA FOIA adverse-event tables. No named individual author — issued under the Citron Research brand. Core rhetorical moves: (1) 83% AAO audience vote used as a single devastating statistic; (2) FOIA-vs-CEO-quote contradiction to pivot from safety critique to securities-fraud allegation; (3) Beovu analogy as the implicit price-path template. No explicit price target or sum-of-parts valuation; the deck is catalyst-driven (FDA warning, litigation) rather than valuation-driven. Closes with a sarcastic 'Did somebody say 83%???' callback echoing the AAO vote.